Deep Dive: CVRM Masterclass From Evidence to Implementation (Durham)

Name: Deep Dive: CVRM Masterclass From Evidence to Implementation (Durham)
SKU: 8751
Availability: InStock

This meeting has been organised by CliniLink Ltd. The sponsors AbbVie, Ascensia Diabetes Care, Daiichi Sankyo, Lupin Healthcare, Novartis, Novo Nordisk, Pfizer Ltd and Recordati, have provided financial support towards this event through sponsorship but have had no input into the meeting agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible for all content.

Pfizer Ltd Promotional Symposium: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is often unrecognised: learn to uncover the clinical clues. This promotional symposium has been developed and funded by Pfizer Ltd and is intended for UK healthcare professionals only. Pfizer Ltd medicines will be discussed.

(PP-UNP-GBR-14748 / PP-UNP-GBR-14952. June 2026).

Novo Nordisk Promotional Symposium:Reducing residual cardiovascular risk in people with established CVD and BMI ≥27 kg/m²:Role of Wegovy®▼ (semaglutide injection)

This is a Novo Nordisk promotional session. Novo Nordisk has provided sponsorship to CliniLink Ltd to cover the cost of this meeting. Novo Nordisk has had no influence over the meeting agenda or arrangements except where indicated.

Ascensia Diabetes Care Symposium. The symposium session, "Diabetes Care: Evolving With You", including the choice of speaker and the content presented, has been developed by and is the sole responsibility of Ascensia Diabetes Care.

See Sponsors below

£0.00

Sponsor This Event

FACE TO FACE EVENT

THIS EVENT IS OPEN TO UK REGISTERED HEALTHCARE PROFESSIONALS ONLY

Location: Ramside Hall, Carrville, Durham DH1 1TD

Event Agenda

Time	Topic	Speaker
09:30-09:50	Registration
09:50-10:00	Introduction and welcome	Beverley Bostock and Professor Ahmet Fuat
10:00-10:15	Pfizer Ltd Promotional Symposium: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is often unrecognised: learn to uncover the clinical clues. This promotional symposium has been developed and funded by Pfizer Ltd and is intended for UK healthcare professionals only. Pfizer Ltd medicines will be discussed. (PP-UNP-GBR-14748 / PP-UNP-GBR-14952. June 2026).	Emma Callan, Therapy Area Specialist Pfizer Ltd
10:15-11:00	Managing Heart Failure in Primary Care – beyond the QoF tick box	Professor Ahmet Fuat
11:00-11:15	Novo Nordisk Promotional Symposium: Cardiovascular Protection Beyond Traditional Therapies: Reducing residual cardiovascular risk in people with established CVD and BMI ≥27 kg/m²: Role of Wegovy®▼ (semaglutide injection)	Novo Nordisk
11:15-11:30	Break
11:30-12:15	CKD – managing the under recognised risk	William Burlace
12:15-13:00	Changing the Hypertension Paradigm - the West Yorkshire guidance	Emily Turner
13:00-13.45	Lunch
13.45-14:00	Diabetes Care Evolving With You	Cathryn Bushby -Ascensia Diabetes Care
14:00-14:05	AbbVie- 5 min Promotional session	Adam Marshall
14:05-15:05	Implementing new NICE diabetes guidance in primary care	Beverley Bostock and Doha Ben-Hamed
15:05-15-30	Break
15:30-16:15	Simplifying Lipid management in Primary Care	Prof Ahmet Fuat
16:15-16:30	Q&A – ask anything CVDRM related	Beverley Bostock and Professor Ahmet Fuat

Learning Outcomes

By the end of the study day, participants will be able to:

Apply an integrated approach to CVRM risk assessment
Optimise RAAS inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and lipid therapy
Manage complex multimorbidity, including HFrEF and CKD
Deliver prevention-focused, holistic reviews that improve long-term outcomes

Key Benefits

Practical application of NICE guidance
Clear decision-making frameworks
Improved confidence in CVRM prescribing
CPD certificate for revalidation

Additional Information

Face-to-face, CPD-accredited event.
Suitable for GPs, prescribing pharmacists, nurses, and primary care MDT members.

Meet the Speakers

Professor Ahmet Fuat

PhD, FRCGP, FRCP, FRCPE ,FESC, FPCCS, PGDiP Cardiology

Honorary Professor, Durham University · GP & GPSI Cardiology (25+ years) · National Programme Director, CliniLink

A Darlington GP for 40 years and one of the UK’s leading voices in primary care cardiology. Professor Fuat established the UK’s first one-stop integrated heart failure clinic in 2002, earned his PhD researching heart failure diagnosis and natriuretic peptides, and has shaped NICE and ESC guidelines on CVD and heart failure — with his HF work featured in the BHF Blueprint for Heart Failure.

Fellow of the RCGP, RCP London, RCP Edinburgh, the ESC and the PCCS, he sits on the editorial boards of the British Journal of Cardiology and the Primary Care Cardiovascular Journal. He teaches because translating evidence into everyday practice is where patient care is won.

Beverley Bostock

RGN, MSc, MA, QN

Bev is an Advanced Nurse Practitioner in long-term conditions. She is currently President Elect of the Primary Care Cardiovascular Society. She has a special interest in cardiovascular disease (CVD), diabetes, heart failure, chronic kidney disease and lipid management along with common comorbidities such as metabolic liver disease, asthma and COPD. She is Editor in Chief of Practice Nurse Journal and has been a Queen’s Nurse since 2015. In a previous role she developed and delivered accredited modules in cardiovascular disease, heart failure and diabetes in collaboration with the Open University. As well as holding an MA in Medical Ethics and Law and an MSc in Respiratory Care, Bev is currently completing an MSc in Diabetes Care with the University of Warwick. Bev has had an extensive range of articles published in various journals on the management of long-term conditions and is a regular speaker at national conferences.

Emily Turner

Emily Turner is the Lead GP Practice Pharmacist for a large practice in Leeds, with a special interest in cardio-renal disease. She has also held the role of West Yorkshire Clinical Lead for CVD Prevention, collaborating across the West Yorkshire Health and Care Partnership to enhance cardiovascular health outcomes. In this capacity, Emily has demonstrated extensive evidence in addressing and reducing health inequalities throughout the system. On a national level, Emily contributes as a member of the England CVDPREVENT Audit Clinical Panel, the National Atrial Fibrillation Expert Advisory Group, and as a Clinical Educator for the Royal Pharmaceutical Society. As an accomplished speaker, she offers valuable expertise and practical guidance to clinicians working in primary care.

Doha Ben-Hamed MPharm IP

MPharm IP

Doha is a senior clinical pharmacist, independent prescriber, and senior lecturer in clinical pharmacy, working across the North East. She has a specialist interest in cardiovascular, renal, and metabolic (CVRM) health within diabetes care and leads on medicines optimisation, clinical education, and system‑wide improvement. Doha is currently undertaking a postgraduate diploma in diabetes, further strengthening her expertise and her commitment to supporting multidisciplinary teams to deliver high‑quality, evidence‑based care for people living with diabetes.

William Burlace

I am clinical pharmacist with over 10 years experience in both community pharmacy and primary care, graduating from the University of Sunderland in 2013. Since completing my independent prescribing at the University of Salford in diabetes and running review clinics, I have specialised more specifically in CKD and general renal medicine. I am currently one of the lead pharmacists on a ICB wide CKD project looking to improve patients' outcomes and raise awareness and improve education in CKD. I am also a board member of the NENC Renal Network, working to solidify relations between secondary care, primary care and the pharmacy sector.

Working to improve patient outcomes, particularly in underserved communities, is a real passion of mine and the importance of close neighbourhood working and education plays a vital role in this.

Sponsor Symposium Sessions